

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED
大成生化科技集團有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock code: 00809)

PROFIT WARNING

This announcement is made by Global Bio-chem Technology Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Directors**”) wishes to inform the shareholders of the Company and potential investors that it is expected that, based on a review of the Group’s unaudited management accounts for the five months ended 31 May 2013, the Group will record a loss in the unaudited interim results (the “**Interim Results**”) of the Group for the six months ending 30 June 2013 (“**Period**”). The Board believes that the loss was primarily attributable to the decline in the price and demand of the Group’s products which in particular, the sale of the Group’s lysine products was affected by the recent emerge of the new bird flu strain and the possible provision for inventories of the Group.

In view of the unfavourable market conditions, the Group has implemented cost control measures by exercising flexible production on its production lines for its lysine products, and has halted the production of its polyol chemicals. The Board believes that the financial position of the Group remains solid. The Group will continue to pursue a prudent approach in financial management and in capital expenditure for adapting to market changes and stabilizing the operations and performance of the Group.

The information contained in this announcement is only based on a preliminary assessment by the Board based on information currently available to it, including the unaudited consolidated management accounts of the Group for the five months ended 31 May 2013, which have not yet been confirmed or reviewed by the Company’s auditors or the audit committee of the Company and finalized as at the date of this announcement. Unaudited financial information of the Group for the six months ending 30 June 2013 will be disclosed in the interim results announcement by the end of August 2013 in compliance with the Listing Rules.

* *for identification purpose only*

Shareholders of the Company and the potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Global Bio-chem Technology Group Company Limited
Liu Xiaoming
Chairman

Hong Kong, 27 June 2013

As at the date of this announcement, the Board comprises three executive directors, namely Mr. Liu Xiaoming, Ms. Wang Guifeng and Ms. Xu Ziyi, and three independent non-executive directors, namely Mr. Chan Man Hon, Eric, Mr. Lee Yuen Kwong and Mr. Li Defa.